type	cutoffType	cutoff	source	entryDate	sourceEvent	sourceUrls	nctId	title	acronym	genderCriterium	countriesAndCities	hospitalsPerCity	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	efficacyDescription	evidenceYear	evidenceLevel	evidenceLevelDetails	direction	evidenceUrls
MICROSATELLITE_UNSTABLE	EQUAL_OR_GREATER	4	CKB_EVIDENCE	2021-02-03	msi	http							Nivolumab			All cancer types	X	Hematologic cancer;2531	efficacy evidence	2024	A	GUIDELINE	RESPONSIVE	http1,http2
MICROSATELLITE_UNSTABLE			CKB_TRIAL	1970-01-01	msi	http	NCT1	study1		both	Netherlands(Rotterdam;Eindhoven),Belgium(Brussel)	Rotterdam(EMC),Eindhoven(Catharina),Brussel(UZ Brussel)	Pembro,Immuno			All cancer types	X	Hematologic cancer;2531		2024	B	GUIDELINE	RESPONSIVE	http3,http4